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Statement of translational relevance  
 
Collectively our data support a clinical trial of rigosertib for treatment of recessive dystrophic 
epidermolysis bullosa-associated squamous cell carcinoma, an inherently aggressive sub-type of 
squamous cell carcinoma with extremely low 5-year survival. Currently there are no effective 
treatments for this devastating cancer and often times initial SCC will recur and readily 
metastasize; any effective systemic therapy that reduces tumor burden will improve quality of 
life in this patient population. 
 
  
Abstract  
Purpose: Squamous cell carcinoma (SCC) of the skin is the leading cause of death in patients with 
the severe generalized form of the genetic disease recessive dystrophic epidermolysis bullosa 
(RDEB). Although emerging data are identifying why patients suffer this fatal complication, 
therapies for treatment of RDEB SCC are in urgent need.  
Experimental Design: We previously identified polo-like kinase 1 (PLK1) as a therapeutic target 
in skin SCC, including RDEB SCC. Here, we undertake a screen of 6 compounds originally 
designated as PLK1 inhibitors, and detail the efficacy of the lead compound, the multi-pathway 
allosteric inhibitor ON-01910, for targeting RDEB SCC in vitro and in vivo. 
Results: ON-01910 (or rigosertib) exhibited significant specificity for RDEB SCC: in culture 
rigosertib induced apoptosis in 10/10 RDEB SCC keratinocyte populations while only slowing the 
growth of normal primary skin cells at doses 2 orders of magnitude higher. Furthermore, 
rigosertib significantly inhibited the growth of two RDEB SCC in murine xenograft studies with no 
apparent toxicity. Mechanistically rigosertib has been shown to inhibit multiple signaling 
pathways. Comparison of PLK1 siRNA with MEK inhibition, AKT inhibition, and the microtubule 
disrupting agent vinblastine in RDEB SCC shows that only PLK1 reduction exhibits a similar 
sensitivity profile to rigosertib.  
Conclusions: These data support a "first in RDEB" phase II clinical trial of rigosertib to assess 
tumor targeting in patients with late stage, metastatic and/ or unresectable SCC.    
Introduction  
 
Patients with the devastating inherited skin disease recessive dystrophic epidermolysis bullosa 
(RDEB) are at significantly increased risk of developing aggressive cutaneous squamous cell 
carcinoma (SCC), which is the cause of death by age 45 years in 70% of individuals with the severe 
generalized form of the disease(1, 2). Furthermore, 5 year survival in all RDEB sub-types 
diagnosed with SCC is close to 0% (2) making RDEB SCC one of the most aggressive forms of this 
tumor type. Current clinical guidelines offer limited treatment options for RDEB SCC and consist 
of wide local excision, radiotherapy, and in late stages, limb amputation (3). New approaches to 
therapy for RDEB SCC are in urgent need. 
RDEB is caused by mutations in COL7A1, the gene encoding type VII collagen (4). However, 
COL7A1 does not behave as a classical tumor suppressor as heterozygous carriers are not at 
increased risk of skin cancer and COL7A1 has not been identified as a significantly mutated gene 
in genetic profiling of any tumor type to date. RDEB is characterized by skin fragility, trauma 
induced skin blistering, and chronic non-healing wounds (5) and work by us and others has 
implicated the tumor microenvironment as a driving mechanism of cancer development (6, 7). 
Our recent comprehensive genetic characterization of RDEB SCC demonstrates that these tumors 
are driven by somatic mutation in driver genes that are identical to UV-induced skin SCC and head 
and neck SCC (HNSCC) (8) and we have consistently been unable to identify genetic mechanisms 
which explain the aggressive nature of RDEB SCC (9, 10).  Our early microarray gene expression 
profiling failed to significantly differentiate RDEB from skin SCC in cultured keratinocytes (10). 
However, this work did identify polo-like kinase 1 (PLK1) as a therapeutic target in RDEB SCC. 
Here we follow up this finding with a screen of compounds originally designated as PLK1 
inhibitors and identify ON-01910, or rigosertib, as a lead candidate for therapy in RDEB SCC. 
 
Materials and Methods 
 
Cell cultures 
Cells were isolated from biopsies taken as part of routine surgical or diagnostic procedures. 
Informed written consent was obtained from each patient or in the case of under-aged children 
from their parents or guardian. This study was performed in accordance with the Helsinki 
declaration. All cells were isolated as described (11) and cultured at 37o C in 5% CO2. 
Keratinocytes were grown in Dulbecco's modified essential medium (DMEM, Corning cellgro, 
Mediatech Inc, Manassas, VA)/ Ham's F12 medium (3:1),  supplemented with 10% fetal bovine 
serum (FBS, PEAK Serum, Cat PS-FB1, Colorado, USA), 10 ng/ml of epidermal growth factor, 10-10 
M cholera toxin, 0.4 μg/ml of hydrocortisone, 5 μg/ml of transferrin, 5 μg/ml of insulin and 13 
ng/ml liothyronine. Supplementary data Table S1 details all cells used in this study. All cells are 
routinely tested for Mycoplasma using either a PCR approach or a colorimetric detection assay 
(MycoAlertTM, Lonza, Allendale, NJ). SCCRDEB2, SCCRDEB3, SCCRDEB70, RDEB84 and RDEB86 
were Mycoplasma positive upon isolation and were treated with PlasmocureTM (InvivoGen, San 
Diego, CA). Only cells which yielded a negative Mycoplasma test were used in the assays 
described. 
 
Protein Quantification 
Total lysates were quantified using Pierce bicinchoninic assay Protein Assay kit (Fisher Scientific, 
Waltham, MA, cat# 23225) and 5-50 g of protein were loaded onto SDS-PAGE gel. The signal 
from Western blot analysis was quantified with Image J. P-CRAF and P-AKT were quantified 
relative to GAPDH.  
 
Drug treatment and western blot analysis 
Rigosertib (ON 01910.Na) was either purchased from Selleckchem.com (Houston, TX) or provided 
by Onconova Therapeutics, Inc. (Newtown, PA). All other drugs were purchased from 
Selleckchem.com. 2-4 x 105 keratinocytes were plated in a 6 well dish. On the following day, the 
medium was changed with the drug at 1 μM or vehicle control. Medium was left for 48 hours and 
cells were lysed with radioimmunoprecipitation assay buffer. Lysate was placed in a centrifuge 
for 5 minutes at 4oC, and the supernatant was mixed with a 6x Laemmli loading buffer. Samples 
were boiled for 5 minutes at 95oC before being loaded onto SDS-PAGE gels. Primary antibodies 
used were: PLK1 (Cell Signaling, 208G4), CRAF polyclonal (Cell signaling, 9422S), P-CRAF (Cell 
signaling, 9427S), P-AKT (Cell signaling, 9271), AKT (Cell signaling, 9272), GAPDH (Santa Cruz 
Biotechnology, 6C5). Resolved proteins were transferred onto nitrocellulose membrane with a 
BioRad Trans-Blot-Turbo (Bio-Rad, Hercules, CA), blocked in TBS-0.1% Tween with 5% milk or 5% 
BSA according to requirements of the primary antibody, and incubated overnight with the 
primary antibody. After incubation with IgG-HRP conjugated secondary antibody (Santa Cruz 
Biotechnology), membrane was incubated with Pierce ECL Western blotting substrate (Fisher 
Scientific) and exposed to CL-XPosure X-ray film (Fisher Scientific).   
 
Immunofluorescence 
RDEB SCC and human control skin biopsies were frozen in optimal cutting temperature (OCT, 
Sakura Finetek USA, Torrance, CA) and cut at 6 microns on a cryostat.  Sections were fixed with 
50:50 methanol: acetone mixture for 5 minutes. Slides were rinsed with 1x PBS, permeabilized 
with PBS/0.1% Tween 20 (Sigma Aldrich, St. Louis, MO) for 5 minutes followed by blocking for 1 
hour with PBST/3% BSA (Sigma Aldrich).  Primary antibodies were incubated for 1.5 hours at room 
temperature.  Secondary antibody Alexa Fluor 594 goat anti-rabbit (1:800, Molecular Probes 
Eugene, OR) was applied for 1 hour at room temperature.  Slides were cover-slipped with hard 
set 4,6-diamidino-2-phenylindole (DAPI; Vector Labs, Burlingame, CA) and examined by 
fluorescence microscopy (EVOS FL cell imaging system, ThermoFisher).    
 
Cell growth and metabolism assays  
Colorimetric assays of mitochondrial dehydrogenase activity were performed using the MTS 
CellTitre 96 AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) 
according to the manufacturer’s instructions. In each case 1-4 x 104 cells were seeded into replica 
96-well plates and readings were taken at intervals up to a maximum of 96 h. We have previously 
shown that an increase in mitochondrial dehydrogenase activity using this assay directly 
correlates with primary non-SCC and SCC cell number determined using a CASY Model TT cell 
counter (Roche Diagnostics Ltd, West Sussex, UK) (10). 
For Crystal violet assay of cell growth, 1-4 x 104 cells were seeded into replica 96-well plates and 
fixed with 70% ETOH at intervals up to a maximum of 96 h. After fixation wells were incubated 
with a solution of 0.2% crystal violet in 2% ETOH for 1 hour at room temperature followed by 
three washes with tap water. Plates were allowed to air dry and were then photographed and 
100 l of 70% ethanol was added to each well for 20 minutes, the plate was agitated to 
homogenize the solution and the absorbance at 595 nm was measured using a plate reader 
(Flexstation 3, Molecular Devices). For photographic quantification black and white images were 
produced using the threshold function in Adobe Photoshop C6 (Adobe) and quantified using the 
measure tool. 
 
Cell Cycle analysis 
 5-Bromodeoxyuridine (BrdU; Sigma-Aldrich) was added to cells at 30 mM final concentration for 
2 hours.  Cells were collected and washed in phosphate-buffered saline, then fixed overnight in 
cold 70% ethanol. RNase A (Sigma) was added at 100 g/ml, in 5% Tween-20 and phosphate-
buffered saline for 30 minutes at 37oC.  Pepsin (Sigma) was added at 1 mg/ml in 30mM HCL for 
30 min at 37oC and DNA was denatured with 2N HCl containing 0.5% Tween-20 in phosphate-
buffered saline for 30 min at 37oC. An anti-BrdU antibody (Invitrogen) diluted in phosphate-
buffered saline/0.1% Tween/ 1% bovine serum albumin was added for 2 h followed by a wash 
with 1% BSA.   After passing the cells through a 70 m filter, Propidium iodide (Sigma) was added 
in the final wash step at a concentration of 25 mg/ml.  Samples were analyzed using a FACScan 
flow cytometer and CellQuest software (Becton Dickinson). 
 
Apoptosis ELISA 
Apoptosis was measured using the Cell Death Detection ELISAPLUS (ROCHE, cat# 11774425001). 
Briefly, non-SCC keratinocytes were plated at 5x103 cells /well and SCC keratinocytes at 2.5x104 
cells /well in 96 well plates. On the next day the cells were treated with the drug (1uM) for 16 to 
24 hours. Cells were lysed for 30 minutes and 20 μl of the lysate was incubated with 80 μl 
immunoreagent (Flexstation 3, Molecular Devices). After incubation the reaction was stopped 
with ABTS solution and absorbance was read using a plate reader at 405 nm and 490 nm. 
 
siRNA knockdown  
siRNA oligonucleotides targeting PLK1 (FlexiTube siRNA, Qiagen, Cat. #: 1027416), a negative 
scrambled control (AllStars Negative Control siRNA, Qiagen, Cat. #: SI03650318) and a positive 
cell death control (AllStars Hs Cell Death siRNA, Qiagen, Cat. #: SI04381048) were used. Cells were 
seeded in six-well plates at 2.5x105 cells/well and 24 h later transfected with siRNA (40 nM final 
concentration) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) diluted in Opti-MEM 
(Invitrogen) according to the manufacturer’s instructions. Cells were left for 16-24h before being 
lysed for Western blotting or trypsinized and seeded in 96-well plates at 5x103 cells/well in 100 
l of media. For comparison of siRNA with vinblastine cells were seeded directly in 96-well plates 
at 1x104 cells/well in 100 l of media and transfected 24 h later as described. 
 
In vivo tumor growth and treatment 
All animal experiments were conducted in accordance with UK Home Office (Project License # 
60/4054) and Thomas Jefferson IACUC (Protocol # 01719) regulations. For tumorigenicity assays 
a suspension of 1–4 x 106 tumor cells was mixed with high-concentration Matrigel (Becton 
Dickinson, Oxford, UK) and injected subcutaneously into the flanks of adult  female SCID Balb/c 
mice (between 6 and 12 weeks of age). Tumors were measured by a caliper and treatment began 
when volume reached 100-200mm3. Animals were treated with 20mg/kg rigosertib dissolved in 
PBS and animals were distributed into treatment or vehicle control groups by alternating 
between treatment (1st animal to reach minimum 100mm3) and vehicle control (2nd animal). For 
the experiment shown in Figure S1, 25 mice were injected with 4x106 SCCRDEB16 cells and BI-
2536 treatment was included as a positive control for 2 animals where every third animal was 
allocated to this group. For the experiment shown in Figure 4, 20 mice were injected with 1x106 
SCCRDEB106 cells. In all cases animals where tumors were attached to the rib-cage or growing 
superficially were sacrificed and not included in the experiment.  
 
TUNEL analysis 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was performed using the 
TACS2 TdT_Fluor In Situ Apoptosis Detection kit (Trevigen, Gaithersburg, MD) according to the 
manufacturer’s instructions. Slides were fixed with mounting medium containing DAPI and were 
viewed under a fluorescence microscope using a 495nm filter. 
 
Statistics 
Paired two-tailed t-test was used for statistical analysis using Prism 8 (GraphPad Software, La 
Jolla, CA). EC50 values were calculated with nonlinear regression using Prism 8.  
Results  
 
PLK1 is increased in RDEB SCC  
We previously identified PLK1 mRNA was increased in 4 RDEB SCC keratinocyte cultures 
compared with normal primary keratinocyte controls (10). Here we extend this observation to a 
total of 10 separate SCC populations and identify PLK1 increased in 10 of 10 fresh frozen RDEB 
SCC tissue samples using immuno-histochemistry (Figure 1). 
 
ON-01910 emerges with the largest delta comparing growth in RDEB SCC and primary skin cells 
After confirmation of increased PLK1 in all RDEB SCC assessed we set out to compare the efficacy 
of commercially available PLK1 inhibitors for targeting RDEB SCC. We initially assessed the effects 
of 6 PLK1 inhibitors on cell metabolism using an MTS assay after 48 hours exposure to normal 
primary keratinocytes (n=1), RDEB primary fibroblasts (n=4), and RDEB SCC keratinocytes (n=4) 
(Table S2). These data identified the compound ON-01910, also known as rigosertib, as having 
the greatest specificity for RDEB SCC keratinocytes when compared with normal primary 
keratinocytes and RDEB primary fibroblasts (Table S2).  
Next, these data were confirmed in all 10 separate patient derived RDEB SCC cell lines using 
crystal violet uptake by live cells after 48-72 hours exposure to varying drug concentrations 
(Figure 2A, B and Figure S1). These data identified clear specificity for RDEB SCC keratinocytes 
when compared with primary normal or primary non-SCC RDEB keratinocytes. We also observed 
that whereas higher concentrations of rigosertib could inhibit the growth of non-SCC primary 
keratinocytes in culture (both RDEB and non-RDEB, Figure 2A and B) no obvious signs of cell 
death were evident while in RDEB SCC keratinocyte populations cell death was widespread 
(Figure 2C). 
 
ON-01910 induces apoptosis in RDEB SCC keratinocytes  
In agreement with our previous data using PLK1 siRNA and the PLK1 inhibitors BI-2536 and GW-
843682 (10), as well as published studies of rigosertib (12-14), exposure of RDEB SCC 
keratinocytes to rigosertib induced cell cycle arrest and apoptosis (Figure 3A-B). 
 
PLK1 siRNA knockdown mimics ON-01910 specificity in RDEB SCC keratinocytes 
Since its identification as an inhibitor of PLK1, rigosertib has been shown to inhibit a variety of 
kinases, including AKT (12) and recently rigosertib has been shown to compete with activated 
RAS for binding to CRAF (15). More recently rigosertib was shown to bind to and destabilize 
microtubules (16) and studies in other malignancies have shown synthetic lethality of PLK1 and 
microtubule destabilizing agents (17).  
To investigate potential mechanisms of action of rigosertib we first exposed RDEB SCC 
keratinocytes to inhibitors of MEK and AKT as well as the microtubule destabilizing agent 
vinblastine. These data showed some efficacy of MEK inhibition at lower concentrations but no 
specificity over normal cells at higher doses, no apparent effect of AKT inhibition and differential 
selectivity of vinblastine (Figure 4A). Next we performed siRNA knockdown of PLK1 and showed 
inhibition of cell growth in all RDEB SCC populations tested (Figure 4B). Four of the populations 
showed only moderate growth inhibition after PLK1 siRNA (45-75%) and in these cells we 
performed siRNA knockdown in the presence of vinblastine but failed to see any overt synergy 
(Figure 4C) as has previously been reported in rhabdomyosarcoma (17). Treatment of RDEB SCC 
keratinocytes with rigosertib inhibited phosphorylation of both AKT and CRAF which was also 
evident after PLK1 siRNA knockdown (Figure S2). 
 
ON-01910 effectively targets RDEB SCC keratinocytes in vivo  
Finally we sought to establish the ability of rigosertib to target RDEB SCC keratinocytes in vivo. 
Tumor xenograft models showed that either local tumor injection (Figure S3) or systemic delivery 
(Figure 4) effectively inhibited the growth of two separate RDEB SCC keratinocyte cell lines in 
vivo. Ki-67 and TUNEL immuno-histochemistry showed that tumors harvested from those 
animals treated with rigosertib had significantly fewer proliferative tumor cells and significantly 
more apoptosis than vehicle control treated animals (Figure 4D and E). Unlike our experiments 
with BI-2536 (Figure S3 and (10)) we did not see any erythema or ulceration of tissue associated 
with the injection site when using rigosertib. 
 
 
 
 
  
Discussion 
 
SCC is a lethal complication for the majority of patients with the already devastating genetic 
disease RDEB and currently there are no approved or effective therapies for SCC in this patient 
population (3). Here we present evidence that the multi-kinase inhibitor rigosertib effectively 
induces apoptosis in 10/10 separate RDEB SCC populations and targets in vivo tumor growth in 
xenograft studies, data which support a clinical trial of rigosertib in RDEB SCC. In particular, the 
lack of significant targeting of non-tumor cells by rigosertib (Figure 2), the lack of any observed 
toxicity in our animal studies coupled with the overall favorable side-effect profile for this drug 
as determined by trials in patients with myelodysplastic syndrome (18) supports the notion that 
even in a patient group such as RDEB, where numerous clinical complications abound as a result 
of lack of mechanical integrity of the epidermis, rigosertib may be well tolerated. 
Previous studies of rigosertib in the context of head and neck SCC (HNSCC) have demonstrated 
similar efficacy in a sub-set of tumor cell lines/ populations (19). The data presented in our study 
show remarkable sensitivity of RDEB SCC to rigosertib and suggests that this subtype of SCC may 
respond to rigosertib treatment more favorably. We have recently increased our current 
understanding of RDEB SCC through comprehensive genomic characterization of 27 tumors, 
including 9/10 cell lines described here (8), which shows that other than mutation burden and 
mechanism, the somatic mutation profile in RDEB SCC is no different to HNSCC or UV induced 
skin SCC, and that RDEB SCC are most similar to the basal and mesenchymal sub-types of HNSCC 
at the level of transcriptomics (8). This similarity to sub-types of HNSCC at the level of mRNA 
expression may begin to offer opportunity for identifying biomarkers of drug sensitivity and we 
are actively pursuing this line of inquiry. Another feature identified in RDEB SCC is homogeneity 
at the level of somatic tumor driver-gene mutation (8) and this may be advantageous in the 
context of targeted therapies where resistance that often develops is associated with genetic 
heterogeneity (20). 
With regard to mechanism of action of rigosertib in RDEB SCC we have investigated pathways 
reported to be targeted by rigosertib and show that only siRNA knockdown of PLK1 has a similar 
profile in targeting all RDEB SCC cell lines with little effect to normal cells (Figure 4). However, 
the level of PLK1 expression did not seem to show any clear correlation with the sensitivity of 
individual RDEB SCC cell lines to either PLK1 siRNA or rigosertib, which does not rule out 
contribution of another pathway when considering RDEB SCC sensitivity to rigosertib over normal 
cells. Further understanding of this sensitivity may offer precision medicine opportunities for use 
of rigosertib in subsets of sporadic SCC arising at different anatomical locations and future work 
will concentrate on understanding the relationship between apoptosis induction and either PLK1 
siRNA or rigosertib exposure in RDEB SCC.  
Finally, the data described here have supported the approval of a clinical trial comparing the 
tolerability and efficacy of rigosertib in RDEB SCC (ClinicalTrials.gov Identifier: NCT03786237) and 
we aim to analyze patient response in the context of biomarker expression, tumor and patient 
genotype, as well as sensitivity of patient material in the laboratory. 
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Tables 
 
Table 1:   
EC50 (M) values as determined by crystal violet assay for 10 RDEB SCC cell lines. 
Cell Line M 
SCCRDEB2 0.1731 
SCCRDEB3 0.2198 
SCCRDEB4 0.1647 
SCCRDEB53 1.567 
SCCRDEB62 0.1977 
SCCRDEB70 0.1741 
SCCRDEB71 0.2165 
SCCRDEB99 0.2197 
SCCRDEB106 0.1496 
SCCRDEB108 0.0834 
  
Figure Legends 
 
Figure 1: PLK1 is increased in RDEB SCC  
A: 5g of total cell lysate was resolved on a 6% SDS PAGE gel, transferred to nitrocellulose 
membrane before being incubated with antibodies raised against PLK1 (Cell Signaling, 208G4) 
and GAPDH (Santa Cruz Biotechnology, 6C5). Samples loaded from left to right: lanes 1-2 = normal 
primary breast keratinocytes (Br61, Br63), lanes 3-6 = RDEB primary keratinocytes (RDEB81, 
RDEB84, RDEB85, and RDEB118), lanes 7-14 = RDEB SCC keratinocytes (SCCRDEB108, SCCRDEB2, 
SCCRDEB3, SCCRDEB70, SCCRDEB71, SCCRDEB4, SCCRDEB62, and SCCRDEB106). B: 6M frozen 
sections were processed and incubated with an antibody raised against PLK1 (Sigma-Aldrich, 
HPA053229) (red) as well as the nuclear stain DAPI (blue). Bar = 400M. 
 
Figure 2: Rigosertib effectively targets RDEB SCC keratinocytes in vitro  
A: Normal primary keratinocytes (FS1, Br61), RDEB primary keratinocytes (RDEB81, RDEB84), and 
RDEB SCC keratinocytes (SCCRDEB2, SCCRDEB3, SCCRDEB4) were seeded into wells of a 96 well 
plate and exposed to vehicle (DMSO) or increasing concentrations of rigosertib (0.01-100uM) for 
48 hrs. Cells were then fixed with 70% ETOH and incubated with the cell dye crystal violet. Plate 
was photographed after excess dye was washed away with water. B: Crystal violet retention was 
measured using a spectrometer and values relative to vehicle alone were calculated for cells 
exposed to increasing concentrations of rigosertib. Left graph shows response curve (±SD) from 
a single experiment using 4 populations of primary non-SCC keratinocytes (Br61, Br63, RDEB81, 
RDEB84) and 10 populations of RDEB SCC keratinocytes. Right graph shows results for RDEB SCC 
cells shown in A after exposure to a wider range of drug concentrations used to determine EC50 
values for all 10 populations of RDEB SCCC keratinocytes (see Table 1 and Figure S1).  C: Cells 
were plated into a 6-well plate and incubated with vehicle alone or 1uM of rigosertib for 48 hrs 
before photographs were taken. Br63 (Primary normal) and SCCRDEB3 cells are shown. 
 
Figure 3: Rigosertib induces G2M arrest and apoptosis in RDEB SCC keratinocytes 
A: Cell-cycle analysis in either RDEB SCC keratinocytes (SCCRDEB2, SCCRDEB3, SCCRDEB4, 
SCCRDEB53, and SCCRDEB106) or non-SCC keratinocytes (Br61, RDEB115, RDEB124) treated with 
rigosertib (1uM, Non-SCC treated and SCC treated) or vehicle control (Non-SCC untreated and 
SCC untreated), and stained for BrdU and propidium iodide. Results expressed as percentage of 
cells at the G0/G1, S and G2/M phases of cell cycle 16 h following treatment. The results shown 
are the mean (±SD) B: Graph shows relative mean absorbance increase using a colorimetric assay 
to detect cleaved nucleosomes in the cytoplasm as a measure of apoptosis after exposure of cells 
to vehicle or rigosertib.  Data shown are the mean (±SD) from two independent experiments 
using 2 populations of normal primary keratinocytes (Br46, Br61), 3 populations of primary RDEB 
keratinocytes (RDEB81, RDEB84, RDEB86) and 10 populations of RDEB SCC keratinocytes (Table 
S1) exposed to 1M of rigosertib for 16-24 hrs. * = p <0.05, ** = p <0.005 (Student t-test). 
 
Figure 4: Rigosertib specificity mirrors PLK1 siRNA knockdown in RDEB SCC keratinocytes  
RDEB SCC keratinocytes (n=9) were exposed to AKT and MEK inhibitors, the microtubule 
disrupting agent vinblastine and PLK1 siRNA knockdown. A: Cells were seeded into wells of a 96 
well plate and exposed to vehicle (DMSO) or drug for 48 hrs. Cells were then fixed with 70% ETOH 
and crystal violet retention was measured using a spectrometer and values relative to vehicle 
alone (100%) were plotted. For each cell line bars indicate the following, left to right: A = AKT 
inhibitor LY294002 0.1M and 5M, T = trametinib 0.1M and 1M, C = cobimetinib 2M and 
5M, V = vinblastine 0.1M and 5M. B: Cells were seeded into wells of duplicate 6 well plates 
and transfected with PLK1 siRNA, scrambled control or a cell death control siRNA. 16 hours later 
one set of cells were trypsinized and transferred to 96 well plates before being fixed 48 hrs later. 
Total cell lysates were isolated from duplicate 6 well plates at the same time as the 96 well re-
seeded plates were fixed. Graph shows cell growth relative to scrambled control siRNA after 
staining with crystal violet while images below show immuno-blotting results with antibodies 
raised against PLK1 (Cell Signaling, 208G4) and GAPDH (Santa Cruz Biotechnology, 6C5). + = PLK1 
siRNA, - = scrambled control siRNA. C: Cells were seeded directly into wells of a 96 well plate and 
transfected with PLK1 siRNA, scrambled control or a cell death control siRNA. 16 hours later cells 
were treated with 1M vinblastine before being fixed 48 hrs later. Graph shows cell growth 
relative to scrambled control siRNA after staining with crystal violet. 
 
Figure 5: Rigosertib effectively targets RDEB SCC keratinocytes in vivo 
Animals bearing SCCRDEB106 xenograft tumors that had reached >100mm3 were treated with 
either rigosertib (n=4) or vehicle control (n=4) injected IP every day for 14 days. Tumors were 
measured with calipers (A) until day 15 when animals were sacrificed, tumors were harvested, 
weighed (B) and photographed (C) before being bisected and frozen or fixed with formalin and 
paraffin embedded. D: 4uM FFPE sections were cut and incubated with an antibody recognizing 
Ki-67 (Abcam, ab16667, 1:200) as well as the nuclear stain hematoxylin. Graph shows the number 
of Ki-67 positive nuclei manually counted from five distinct microscopic fields for each tumor 
(n=8) at 20× magnification. E: 4M FFPE sections were cut and incubated with an antibody 
recognizing TUNEL (HERE) as well as the nuclear stain DAPI. Graph shows the number of TUNEL 
positive nuclei per cell calculated using ImageJ software. * = p <0.05, ** = p <0.01, *** = p <0.001 
(Student t-test). 
 
